McKesson Makes Med/Surg Leadership, Process Changes To Boost Results
This article was originally published in The Gray Sheet
McKesson remains committed to its $684 mil. Medical-Surgical Solutions segment, citing untapped potential in the alternate-site health care market
You may also be interested in...
McKESSON'S $775 MIL. GENERAL MEDICAL BUY GIVES DRUG WHOLESALER ENTRY INTO MED/SURG, ALTERNATE SITE MARKETS; DEAL INCLUDES ASSUMPTION OF $428 MIL. DEBT
McKesson's $775 mil. acquisition of General Medical gives the nation's largest pharmaceutical wholesaler a medical/surgical distributor with strength in the alternate site market.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.